Group 1 - The Law Offices of Howard G. Smith announced a securities fraud class action lawsuit against Metagenomi, Inc. for investors with substantial losses since the company's IPO in February 2024 [1] - The lawsuit alleges that Metagenomi failed to disclose that its collaboration with Moderna would terminate in the immediate future, which misled investors regarding the company's business prospects [2] - Investors are encouraged to contact the law firm to discuss their legal rights and options regarding the class action [3]

NEW YORK, Oct. 7, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Metagenomi, Inc. (NASDAQ: MGX). Shareholders who purchased shares of MGX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/metagenomi-loss-submission-form/?id=106647&from=4 CLASS PERIOD: This lawsuit is on behal ...

Core Viewpoint - The article discusses a class action lawsuit against Metagenomi, Inc. following its IPO, highlighting the deadline for investors to file a lead plaintiff motion and the alleged misleading statements made by the company regarding its collaboration with Moderna [1][4]. Group 1: Company Overview - Metagenomi, Inc. conducted its IPO on February 13, 2024, selling approximately 6.25 million shares at $15 per share [3]. - Following the announcement of the termination of its collaboration with Moderna on May 1, 2024, Metagenomi's stock price dropped by $0.87, or 12.4%, closing at $6.17 per share on May 2, 2024 [3]. Group 2: Legal Proceedings - A class action lawsuit has been filed on behalf of investors who purchased Metagenomi securities during the IPO, with a deadline of November 25, 2024, to file a lead plaintiff motion [1][6]. - The complaint alleges that the defendants made materially false and misleading statements and failed to disclose adverse facts about the company's business and prospects, particularly regarding the collaboration with Moderna [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Metagenomi, Inc. due to alleged violations of federal securities laws related to misleading statements about its collaboration with Moderna, which has led to significant investor losses [3][4][5]. Group 1: Company Overview - Metagenomi, Inc. is described as a "genetic medicines company" that had a collaboration with Moderna, a leading Covid-19 vaccine company [4]. - The company completed its initial public offering on February 13, 2024, selling 6.25 million shares at $15 per share [5]. Group 2: Legal Investigation - The law firm is encouraging investors who suffered losses exceeding $50,000 between February 9, 2024, and September 26, 2024, to discuss their legal rights [1]. - A federal securities class action has been filed against Metagenomi, with a deadline of November 25, 2024, for investors to seek the role of lead plaintiff [1][6]. Group 3: Allegations and Impact - The complaint alleges that Metagenomi and its executives made false or misleading statements regarding their collaboration agreement with Moderna [3]. - Following the announcement of the termination of the collaboration agreement on May 1, 2024, Metagenomi's stock price fell from $7.04 to $6.17 per share within a day, indicating a negative market reaction [5].

Core Viewpoint - A class action lawsuit has been filed against Metagenomi, Inc. for allegedly misleading statements made during its IPO, particularly regarding its collaboration with Moderna, which was terminated shortly after the IPO [1][3]. Company Overview - Metagenomi, Inc. conducted its IPO on February 12, 2024, selling approximately 6.25 million shares at $15 per share [2]. - The company positioned itself as a "genetic medicines company" with a longstanding relationship with Moderna, a leading Covid-19 vaccine company [3]. Recent Developments - On May 1, 2024, Metagenomi announced the termination of its collaboration with Moderna, leading to a significant drop in its share price from $7.04 to $6.17, a decline of $0.87 or 12.4% [2]. Legal Proceedings - Investors who acquired Metagenomi securities during the class period from February 9, 2024, to May 1, 2024, have until November 25, 2024, to apply to be appointed as lead plaintiff in the lawsuit [1].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Metagenomi, Inc. regarding a class action lawsuit related to the company's initial public offering and subsequent termination of its collaboration with Moderna [1][3]. Group 1: Company Overview - Metagenomi, Inc. is characterized as a "genetic medicines company" that had a significant partnership with Moderna, which was highlighted during its initial public offering [3]. - The company completed its IPO on February 13, 2024, selling 6.25 million shares at a price of $15 per share [3]. Group 2: Allegations and Impact - The lawsuit arises from allegations that Metagenomi misled investors about its collaboration with Moderna, which was a critical aspect of its business model [3]. - Following the announcement of the termination of the collaboration on May 1, 2024, Metagenomi's stock price fell from $7.04 to $6.17 within a day, indicating a significant market reaction to the news [3]. Group 3: Legal Proceedings - The class action lawsuit is on behalf of shareholders who purchased stock during the IPO period from February 9 to 13, 2024 [2]. - Shareholders are encouraged to register for the class action by November 25, 2024, to potentially become lead plaintiffs and to receive updates on the case [4].

NEW YORK, Oct. 1, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Metagenomi, Inc. ("Metagenomi" or the "Company") (NASDAQ: MGX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Metagenomi investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of all shareholders that purchased stock pursuant and/or traceable to Metagenomi's registration statement for the initial public offering held between Februa ...

NEW YORK, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Metagenomi, Inc. ("Metagenomi" or the "Company") (NASDAQ: MGX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Metagenomi investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of all shareholders that purchased stock pursuant and/or traceable to Metagenomi's registration statement for the initial public offering held between ...

NEW YORK, Sept. 30, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Metagenomi, Inc. (NASDAQ: MGX). Shareholders who purchased shares of MGX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/metagenomi-loss-submission-form/?id=105586&from=4 CLASS PERIOD: This lawsuit is on beh ...

Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of purchasers of Metagenomi, Inc. stock related to its IPO conducted in February 2024, following the termination of a collaboration agreement with Moderna, which allegedly caused investor damages [1][5]. Group 1: Lawsuit Details - The class action lawsuit pertains to Metagenomi's IPO, where 6.25 million shares were sold at $15 each [5]. - The lawsuit claims that Metagenomi misrepresented its business relationship with Moderna, which was terminated less than three months after the IPO [5]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Next Steps for Investors - Investors wishing to join the class action can do so by visiting the provided link or contacting the law firm directly [3][6]. - A lead plaintiff must file a motion with the court by November 25, 2024, to represent other class members [1][3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest against a Chinese company [4]. - The firm has been consistently ranked among the top firms for securities class action settlements since 2013 [4].